Ranibizumab biosimilar is under clinical development by Lupin and currently in Phase III for Wet (Neovascular / Exudative) Macular Degeneration. According to GlobalData, Phase III drugs for Wet (Neovascular / Exudative) Macular Degeneration have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Ranibizumab biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ranibizumab biosimilar overview
Ranibizumab biosimilar is under development for the treatment of wet macular degeneration. It is administered as intravitreal injection. It acts by targeting VEGFA. The drug candidate is produced using high performance clonal cell lines using proprietary vectors in conventional host systems. The cell lines aid in enhanced expression of therapeutic proteins.
Lupin develops and manufactures generic and branded formulations, biotechnology products, and active pharmaceutical ingredients (APIs). It has expertise in the areas of cardiovascular, asthma, diabetic management, pediatrics, central nervous system, gastro-intestinal, anti-infectives, nonsteroidal anti-inflammatory drugs (NSAIDs), anti-TB, and cephalosporins. The company undertakes extensive research and development activities of pharmaceuticals for the treatment of migraine, gastrointestinal, psoriasis, central nervous system, cardiovascular, tuberculosis, diabetes, inflammation and others. Lupin also develops value-added generic pharmaceuticals based on its platform technologies. The company along with its subsidiaries operates manufacturing facilities in India, the US, Mexico, and Brazil. Lupin is headquartered in Mumbai, Maharashtra, India.
For a complete picture of Ranibizumab biosimilar’s drug-specific PTSR and LoA scores, buy the report here.